Thursday, 24 October 2013

Meth: I choose you! Does study show addicts' choices are ultimately rational?

This post is a slightly modified version of one that was written by Jay Duckworth and posted on his own blog. 


Last month (16/09/13) The New York Times published an article in their science section entitled The Rational Choices of Crack Addicts, which was promoted online by numerous sources and proved to be quite popular. Incidentally, this popularity is evidenced by the numerous iterations of the original piece in various media outlets (some of which can be seen here, here, here, here, here, here and here). The version published in The Atlantic further enjoyed a promotional tweet by the famous Harvard psychologist Steven Pinker:

The Science of Choice in Addiction - Sally Satel - The Atlantic http://t.co/txYAoPjUC2
— Steven Pinker October 2, 2013
The articles possess the same basic implication - that the predominant view of addicts as zombie-like creatures bound by their compulsion is wrong, and now we have evidence to prove it. The problem with this, however, is two-fold: first, the view outlined above is not the predominant view of most addiction researchers, but a caricatured version of a more measured and nuanced conception (Marc Lewis's description of addiction as "biased choice" succinctly parses this quite well; he also has a piece tackling a similar subject to this post). The second part of the problem is that the conclusions of many of the media outlets vastly exaggerate the reach of the study they cite.

The study in question is that of Kirkpatrick et al. (2012): Comparison of intranasal methamphetamine and d-amphetamine self-administration by humans - a title rendered sufficiently bland by its competitors in the media (Gawker's headline was Why Everything You Know about Crack Addiction is Wrong). The study's primary aims were to test the effects of different molecular amphetamines on cardiovascular health and psychomotor performance, as well as users' subjective experiences (i.e. ratings of mood change and behaviour towards each drug).

The general procedure (of interest here) was as follows; participants were subjected to two different sessions on two different days - the first was a "sample" session in which participants were provided with samples of both drug and monetary rewards; the second a "choice" session wherein these rewards were actively chosen by participants during a computerised task. Depending on their choices, participants received either some ratio of drugs and money, or maximal amounts of either reward. Participants were also assigned to either a high value condition or low value condition; those in the former received $20 on sample days and had the option of obtaining $20 on choice days (given they chose only monetary options during the task), while those unfortunate enough to be assigned to the latter condition received only $5. (Drug doses were the same for each condition.)

It was found that those in the $5 condition possessed no strong preference for a single reward, with only a slight choice tendency towards the money (59%). Those in the $20 condition, however, were far more likely to choose money over drugs, with 83% of options chosen being monetary. The authors concluded that when given a valuable-enough alternative, participants could be dissuaded from drug self-administration: a reasonable conclusion. The media then took this modest hatchback of a conclusion and inflated it to Ferrari-like proportions. The labelling of the media's conclusions as exaggerated is justified for two reasons: first, such significant conclusions are unlikely to ever be validated by a single study (this, as a rule, is not how science generally works). Second, such conclusions based on this particular study would be unwise given its numerous limitations.

We can first consider flaws with the study's cohort. With just 13 participants, the study's sample size was small; but further, since the design was between subjects (meaning conditions are effectively analysed separately) this reduces the numbers further to just 6 and 7 participants in each condition. These numbers are minuscule. Moreover, all participants were male and self-selected - none had ever sought help for their drug use nor were they interested in receiving any - meaning that what we might have here is a particular subgroup of drug users with different goals, intentions, personalities and experiences with drugs, which do not apply to many others not in this group. Furthermore, the authors note that only three of the participants met the criteria for drug dependence - this is only 23% of an already tiny sample! Overall this means that any conclusions derived from this study cannot simply be extrapolated to clinical populations.

There also exist problems with the study's design (given the conclusions of the media). Since participants were automatically supplied with drugs on "sample" days, we cannot make any solid deductions about whether the same results would be garnered in periods of abstinence. Also, given that many of the participants may have been occasional users, a hit of meth every few days may have been ample, meaning the only real option to go for would have been money anyway. This also means that the employed strategy of many may have been to sequester funds for purchase of drugs after the experiment was over. However, this is unlikely to have been the case - at least if the plan was to spend the monetary rewards on meth. The values of the drug and monetary rewards over the course of the study were well matched ($60-$80 and $100, respectively), and given the average dose of meth (250mg) will set you back around $80 on the streets of New York (the study's location), the participants would receive the same amounts of meth whether they obtained it from the researchers during the study or from Walter White afterwards (Breaking Bad references are still going strong, right?).

However, another small problem appears when we consider that these participants were also users of cocaine and marijuana, both of which are cheaper than meth (marijuana substantially so; see Table 1).
Illicit drugs prices in New York City: 1lb
Meth
~$15,000
Cocaine
~$12,000
Marijuana
~$2,000 - $3,000
Table 1: The links for these estimates can be found in the reference section.

This means that the above strategy would still be valid when applied to these other drugs, and so again any inference that these results alone show the way forward in how we treat addicts is mistaken. Finally, the doses used in this study were 5-20 times lower than average street use, and simply scaling these results upward and assuming they would remain the same is bad practice.

So as we can see, though this is by no means the worst study you're likely to find, the conclusions made by the media extended far beyond the study's grasp. This is a shame, not just because scientific research has been misrepresented - though this would surely be enough - but also because there are other studies out there which actually test whether alternative monetary reinforcers dissuade addicts' drug inclinations, and they support the results found here. Some might ask "Then why write this article?!" But to ask this question would be to miss the point. The point here is not to say that offering alternative reinforcers to addicts could never work, but to highlight the fact that this lone study could never provide the evidence necessary to show that it does. In the progress of science, evidence is more often than not carefully accumulated, not acquired in its entirety. The media would do well to remember this.

References:

Hser, Y. I., Huang, D., Brecht, M. L., Li, L., & Evans, E. (2008). Contrasting trajectories in Heroin, Cocaine and Methamphetamine use. Journal of Addictive Diseases, 27, 13-21.

Kirkpatrick, M. G., Gunderson, E. W., Johanson, C., Levin, F. R., Foltin, R. W., & Hart, C. L. (2012). Comparison of intranasal methamphetamine and d-amphetamine self-administration by humans. Addiction, 107(4), 783-791.


Wednesday, 23 October 2013

We are the Addiction research group and are based in the Department of Psychological Sciences, University of Liverpool.



Professor Matt Field (research group leader): I'm a Professor of Psychology at the University of Liverpool. I studied at the Universities of Swansea and Sussex, and then worked as a postdoc at the University of Southampton before moving to Liverpool in 2004. My primary interests are the cognitive and motivational processes that underlie heavy drinking and other types of substance use. For example, I am interested in the roles of attentional bias, and  impulse control in the development of  problem drinking, and their influence on  alcohol consumption in the laboratory. My research has been funded by the Medical Research Council, Wellcome Trust, Economic and Social Research Council and Alcohol Research UK.  on twitter




Dr Abi Rose: I have been a Lecturer in Psychology at the University of Liverpool since 2010. I obtained my PhD in Experimental Psychology from the University of Sussex in 2006, and then worked as a postdoc at St George’s Medical School, UCL, before taking an appointment as Lecturer at the Institute of Psychiatry, KCL. My research interests are focused around the psychopharmacological basis of addiction and specifically identifying pathways into and out of hazardous drinking. My laboratory-based research investigates the processes involved in drinking, including the interaction between environmental and intoxication effects, while my clinical research focuses on developing more effective psychosocial treatments and pharmacotherapies. For example, I am interested in the priming effects of alcohol, the learning mechanisms underlying drinking behaviour, and the pharmacological basis of alcohol dependence. My research has been funded by the Medical Research Council, Economic and Social Research Council, and Alcohol Research UK. Follow @abirose9 on twitter.



Dr Paul Christiansen: I have been a Lecturer in Psychology at the University of Liverpool since 2013. I obtained my PhD in Experimental Psychology from the University of Liverpool in 2012, and taught extensively while doing my PhD. My research interests are focused around self control over drinking. For example I have recently investigated the influence of self control depletion on drinking in the laboratory. I have also conducted research into the acute and anticipated  effects of alcohol on automatic and executive cognitive processes and how these processes relate to the alcohol priming effect.  I am also interested in the development of personalised stimuli for use in the assessment of attentional bias. My research has been funded by Alcohol Research UK. Follow @ChristiansenLiv on twitter. 



Dr Charlotte Hardman: I have been a Lecturer in Psychology at the University of Liverpool since 2013. I studied at the University of Leeds (BSc) and Bangor University (PhD) and then worked as a postdoc at the University of Bristol. My research examines the psychological and biological control of appetite, food intake and addictive behaviours. For example, I am interested in affective and non-affective determinants of food reward (“liking” and “wanting”) and the influence of cognitive factors, such as attention, memory and expectations, on the amount of food that people consume. I am also interested in the extent to which over-eating can be thought of as an addictive behaviour. My research has been funded by the Economic and Social Research Council and the Welsh Assembly Government. Follow @CharlotteHardm3 on twitter. 





Dr Eric Robinson: I am a tenure-track research fellow and have worked at the University of Liverpool since 2013. I am interested mainly in social context and alcohol use – why is it often the case that people around us will influence how much we drink and why does this happen? I am also keen on examining how beliefs we hold about ourselves and others can shape alcohol and drinking behaviour.


I also do work examining eating behaviour and obesity, which can be found here – http://www.liv.ac.uk/psychology-health-and-society/staff/eric-robinson/. Follow @eric_robinson_ on twitter. 


Dr Andrew Jones (Post-doc): I studied for both my undergraduate degree in psychology and my PhD at the University of Liverpool before starting my post-doc in December 2012. My primary interest is the relationship between impulsivity and alcohol-use. My work involves examining ‘state’ fluctuations in (dis)inhibition, and whether they can influence alcohol-seeking (see here and here). I am also interested in general processes that underlie motivated behaviours, such as attention. Follow @ajj_1988 on twitter.  






Elly McGrath (Research assistant): I have completed a Bachelor’s degree in Psychology from the University of Manchester. I have previously worked as a Research Assistant on an NIHR funded project investigating a CBT intervention for Bipolar Disorder and co-morbid anxiety and a project running an online intervention with the Royal Liverpool University Hospital for patients experiencing difficulties managing their emotions in relation to cancer. I am currently working on the Medical Research Council grant on state disinhibition and heavy drinking, and my interests are in cognitive processes and cultural influences concerning alcohol use and non-specific effects of addiction treatment



Natasha Clarke (First year PhD student): I studied for both my undergraduate and Master’s degree at the University of Liverpool. My interest is in methods and approaches that can be used to reduce the harm associated with excessive drinking and my current research focuses on the effectiveness of brief interventions in reducing unit consumption in young adults. My research is funded by the Economic and Social Research Council and Alcohol Research UK. Follow @tash_c135 on twitter. 






Jay Joseph Duckworth (First year PhD student): I am studying psychopharmacology at the University of Liverpool. In particular I’m attempting to find out whether work with non-human animals into sign-tracking and goal-tracking behaviours can be extrapolated to humans, using both cognitive and behavioural measures to accomplish this. I’m also interested in the wider scope of psychopathology. Follow @JayDuckworth on twitter. 




Lisa Di Lemma (First year PhD Student): I am investigating “Overcoming  disinhibition and retraining automatic tendencies in heavy drinkers and tobacco smokers”. I studied Psychology in Rome and moved to London in 2011 for my Masters in Research Methods and Psychology in London City University. In 2012-2013 I worked as a Research Assistant in the University of Liverpool, investigating the role of Motivational Ambivalence in predicting relapse in alcohol dependent patients. My research interests are currently focused on cognitive and motivational process in heavy drinkers and smokers. In particular I am interested on: Disinhibition, Implicit Motivational Tendencies and Motivational Ambivalence. Follow @DiL_Lisa on twitter. 




Inge Kersbergen (First year PhD student): I have completed a Bachelor in Psychology and Research Master in Behavioural Science at the University of Nijmegen, the Netherlands. I’m mainly interested in automatic processes that guide behaviour. My PhD is funded by the UK Centre for Tobacco and Alcohol Studies (UKCTAS) and will look into cognitive processing of advertisement and warning labels on alcohol and tobacco products and their effect on behaviour.







PaweÅ‚ JÄ™dras (Second year PhD student): I hold a Master’s degree in psychology of addictive behaviours and Bachelor’s degree in psychology from the University of Liverpool. During my Bachelor’s project I analysed the role of planned behaviour and impulsivity in predicted and actual alcohol consumption, especially emphasising potential applications of cusp catastrophe in modelling of heavy episodic drinking, whereas my Master’s thesis was about the effects of thought suppression on alcohol approach bias after priming of positive or negative alcohol-related information. Although my current research is mainly focused on the effects of reward and punishment anticipation on the attentional bias in the visual processing of motivationally salient stimuli, I am also interested in various issues related to addiction including historical and cultural aspects of drugs and drug policy.




Helen Ruddock (First year PhD student): My main areas of interest include appetite, obesity and addiction. Currently, my research focuses on the behavioural and cognitive manifestations of ‘food addiction’.  Prior to starting my PhD, I completed a BSc in Psychology at the University of Plymouth, and an MSc in Neuropsychology at the University of Bristol. During my MSc, I conducted research into the role of loss aversion on food portion-size selection. Follow @helzbelz1984 on twitter. 


Tuesday, 22 October 2013

New drug has potential to treat marijuana addiction

This is the original version of an article that was written by Matt Field and edited for The Conversation, you can find that version here. 

More than 1.2 million Americans per year seek treatment for problems with their marijuana (or cannabis) use. Cannabis use disorder is recognised in the same category as other substance use disorders (‘addictions’), in the Diagnostic and Statistical Manual of Mental Disorders, and up to 1% of the European population may warrant this diagnosis. Psychological treatments such as motivational interviewing and cognitive behaviour therapy may be effective, although there have been very few controlled trials of these therapies. A recent review concluded that there were no effective medications for the prevention of relapse to cannabis use.

Like other addictive drugs, Delta-9-tetrahydrocannabinol (THC; the main psychoactive ingredient in cannabis), produces its rewarding effects by stimulating dopamine release in the brain’s reward system, a network of brain structures including the Nucleus Accumbens (NAcc) and the ventral tegmental area (VTA).   Therefore, one potential way to treat addictions would be to give medications that block dopamine activity in the reward system, such as the dopamine antagonist drugs that are used to treat schizophrenia. Unfortunately, these drugs have some unpleasant side-effects. More fundamentally, dopamine antagonists block all forms of reward, not just drug-induced reward. Therefore, the search is on for drugs that can interfere with drug-induced reward without producing unpleasant side-effects, and without interfering with the response to other rewards.

            A study recently published in Nature Neuroscience has identified a promising potential new medication for cannabis use disorders. The drug, RO 61-8048, leads to increases in levels of kynurenic acid (KYNA). Through a fairly complicated mechanism, what this does is block the ability of THC (and similar compounds) to increase dopamine activity in the brain’s reward centre. Most importantly, although the drug can blunt the effect of THC on dopamine levels, it has no effect on dopamine levels when given on its own. In this paper, the authors conducted a series of studies with rodents and primates, and they found that:

  • The drug prevented the increase in dopamine levels in NAcc and the VTA that normally occurred after infusion of THC.
  • The drug blocked the reinforcing effects of THC: after receiving the drug, animals were less likely to press a lever in order to obtain injections of THC or a related compound.
  • The drug could block the rewarding effects of THC. For example, animals will normally press a lever to receive THC if they have just been given an injection of THC or if they have been presented with environmental signals that THC was available (these tests are considered animal models of relapse to drug use). The drug reduced both of these effects.
  • These effects of the drug were specific to THC, because the drug did not affect the reinforcing properties of another reward: food. Animals were prepared to press a lever in order to win food pellets, regardless of whether they had received the drug or not.
  • At the doses studied, the drug had no effect on working memory, and did not change the memory-impairing effects of THC. 


These findings are potentially important because has been very difficult to develop medications that block drug-induced reward without also interfering with the response to other rewards. The safety of the drug, and its effectiveness as a treatment for cannabis use disorders, should now be studied in human volunteers.

We should be cautious, however. Even if the drug is safe in humans, and it can reduce the rewarding effects of cannabis, this will not make it a panacea for cannabis use disorders. Medications for other substance use disorders, such as naltrexone for alcohol use disorders and buprenorphine for opiate use disorders are prescribed because they reduce the rewarding effects of alcohol or heroin if those drugs are consumed. Although the drugs are effective, if a patient decides that they want to experience the rewarding effects of alcohol or heroin again, all they have to do is stop taking their medication. This is also likely to be the case for RO 61-8048 and cannabis use disorders. Medication implants and depot formulations may partly solve this problem.


Thursday, 10 October 2013

Is the adolescent brain wired for addiction?

This article was written by Matt Field.It started out as an opinion piece for the University of Liverpool news pages.  It was then slightly modified as a 'Hard Evidence' piece for The Conversation, and then somehow it ended up on the New Statesman site.
As a nation, we are drinking much more than we used to, which is partly attributable to alcohol being cheaper and more available than ever. Many British teenagers get into the habit early, although recent trends suggest this situation is improving (alcohol consumption among teenagers is slightly lower than it was ten years ago).
Nonetheless, drinking alcohol during adolescence is not a good idea, because the younger you are when you have your first alcoholic drink, the more likely you are to develop problems later on in life. The same is true for cigarette smoking and the use of illicit drugs such as cannabis and cocaine.





Rates of teenage drinking are dropping. NatCen
Click to enlarge

Arrested development

Why are adolescents particularly vulnerable to addiction? A large part of the answer comes from our understanding of the neurobiology of brain development during adolescence. The brain does not reach maturity until fairly late in life, with new connections between brain cells being formed right up until people are in their mid-20s.
Importantly, the brain does not mature at a uniform rate. The more primitive regions of the brain, including the reward system and other areas of the subcortex such as those parts that process emotions, reach maturity relatively early (when people are in their early teens).





The prefrontal cortex is a late bloomer. National Institute of Health

The more “advanced” parts of the brain, such as the prefrontal cortex, are not fully developed until much later. In behavioural terms this means adolescents are particularly sensitive to their emotions and to things that are novel and motivationally appealing, but they are relatively unable to control their behaviour and plan for the future.

Taking risks

My research suggests this can explain why some adolescents drink more than others: teenagers who were relatively poor at exerting self-control, or who took more risks on a computer test of risk-taking, were more likely to drink heavily in the future.
This creates perfect conditions for vulnerability to addiction during adolescence, because the motivational “pull” of alcohol and other drugs is very strong, whereas the ability to control behaviour is relatively weak. Many scientists think if adolescents do drink a lot, and if they do it frequently, then this might cause long-lasting changes in the way that the brain is organised, which can make it very difficult to stop drinking.
We certainly see changes in the brains of people with alcohol problems (compared to people without problems), but it can be difficult to work out if alcohol caused those brain changes, or if those people had slightly different brains before they started drinking, and these subtle differences may have led them to start drinking in the first place.





Starting early carries greater risk. NatCen

Addiction and behaviour

In principle, adolescent brains could be vulnerable to “behavioural” addictions as well as alcohol and drug addiction, for exactly the same reason. Very few behavioural addictions are officially recognised by psychiatrists and psychologists at the moment (gambling addiction is the only exception).
The Channel 4 documentary Porn on the Brain shown this week asked whether pornography is addictive, and if adolescents could be getting hooked. As shown in the programme, it certainly seems to be the case that a minority of adolescents who use pornography exhibit some of the characteristic features of addiction, such as feeling unable to control their use of porn, and loss of interest in other activities.
Their patterns of brain activity when viewing porn seem to be similar to those seen in people with alcohol and drug addictions when they look at pictures of alcohol and other drugs. It remains to be seen whether addiction to porn will eventually be recognised as a psychological disorder, but it is clear that it can create problems for some adolescents and young adults who use it.
What can be done? Although it’s obvious, parents should do what they can to prevent their children from experimenting with alcohol, smoking and other drugs for as long as possible. The same applies to other things that might eventually be considered “addictive”. School-based prevention programmes can also be successful, including a recent program that is tailored to different personality types and has shown some promise at reducing alcohol consumption in teenagers.